Research programme: antibacterials - Novexel

Drug Profile

Research programme: antibacterials - Novexel

Alternative Names: AVE 2221A; AVE 6971; AVE 6971A; NXL 105

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Novexel; sanofi-aventis
  • Developer Novexel
  • Class Quinolines
  • Mechanism of Action Cell wall inhibitors; DNA topoisomerase inhibitors; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Pseudomonal infections

Most Recent Events

  • 18 Mar 2009 Preclinical trials in Pseudomonal infections in France (unspecified route)
  • 18 Mar 2009 Novexel has selected NXL 105 as a lead candidate for further preclinical development in Pseudomonal infections
  • 16 Aug 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top